XSHE
300006
Market cap847mUSD
Oct 09, Last price
5.47CNY
1D
1.86%
1Q
12.78%
Jan 2017
-35.27%
IPO
22.23%
Name
Chongqing Lummy Pharmaceutical Co Ltd
Chart & performance
P/E
—
P/S
7.51
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.19%
Rev. gr., 5y
-8.90%
Revenues
769m
-3.35%
Net income
-135m
L+53.42%
CFO
61m
-66.86%
Dividend
Jul 03, 20200.05 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Chongqing Lummy Pharmaceutical Co., Ltd. is a Chinese firm dedicated to the research, development, production, and distribution of a broad spectrum of pharmaceutical products. Its extensive portfolio encompasses treatments for various therapeutic areas, including oncology, infectious diseases (antibacterial, antiviral, and antifungal), liver support, and endocrine disorders. The company also develops and markets medications for the digestive, immune, blood, cardiovascular, and nervous systems, in addition to traditional Chinese patent medicines. Further offerings include electrolyte and acid-base balancing agents, nutritional supplements, large volume parenteral solutions, American ginseng preparations, and active pharmaceutical ingredients. Established in 1999, the company's headquarters are located in Chongqing, China.
Key people
Yu Qiu
Chairman of the Board, General Manager · since 2002
Xuefeng Leng
Vice Chairman of the Board · since 2016
Wen Lai
Chief Financial Officer · since 2016
Rong Fu
Deputy General Manager · since 2005
Bin Zhao
Deputy General Manager · since 2005
Jiangfu You
Vice Chairman of the Board
Chunlin Zhao
Director
Xiaohua Diao
Independent Director
Independent Director
Headquarters & legal address
重庆市南岸区玉马路99号
南岸区, CQ 100000
CN
南岸区, CQ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||